Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.09.022Source: DataRank Database

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2021). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.66)OA: greenTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Matthew L. Smith ORCID,Hua‐Ling Tsai ORCID,Ravi Varadhan ORCID,Amy E. DeZern ORCID,W. Brian Dalton ORCID

Live enrichment

PubMed:34750086 PMC:PMC8977228 OpenAlex:https://openalex.org/W3207941514

National Institutes of Health

Grant: T32 CA009071

National Cancer Institute

Grant: P30 CA06973

National Cancer Institute

Grant: PO1 CA225618

NCI NIH HHS

Grant: K08 CA218893

NCI NIH HHS

Grant: P01 CA225618

NCI NIH HHS

Grant: P30 CA006973

American Society of Hematology

Bristol-Myers Squibb

Merck

Gilead Sciences

Novartis

CTI Biopharma

FWCI

0.66

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8977228

publisherhttps://api.elsevier.com/content/article/PII:S2152265021020711?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265021020711?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.clml.2021.09.022

Fields of Study

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationImmune Response and Inflammation

MeSH Terms

CyclophosphamideHumansIsocitrate DehydrogenaseMutationPrognosisTransplantation, HomologousLeukemia, Myeloid, AcuteHematopoietic Stem Cell Transplantation

Keywords

MedicineInternal medicineCumulative incidenceSingle CenterMyeloid leukemiaHazard ratioUnivariate analysisIncidence (geometry)Proportional hazards modelGastroenterologyIDH1TransplantationCyclophosphamideOncologyMultivariate analysisConfidence intervalChemotherapyMutationAcute myeloid leukemiaBone marrow transplantOutcomesIsocitrate Dehydrogenase MutationsIsocitrate Dehydrogenase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being